Kornam, tablets 5 mg 30 pcs

Cornam is a blocker of peripheral postsynaptic a₁ adrenoreceptors.

Induces dilation of arterioles and venules, decreases OPPS and venous return to the heart, resulting in a decrease of BP.

The hypotensive effect lasts for 24 hours after a single dose of the drug.

Blocking a₁ adrenoreceptors of smooth muscles of prostate and bladder neck promotes normalization of urination in patients with benign prostatic hyperplasia.

The drug helps normalize lipid metabolism: it reduces cholesterol, triglycerides and low and very low density lipoproteins in the blood while increasing the amount of high density lipoproteins.

With systematic use of Kornam there is regression of left ventricular hypertrophy.

Indications

Active ingredient

Composition

1 tablet contains:

Therazosin (in the form of dihydrate hydrochloride) 5 mg.

Auxiliary substances:

Lactose monohydrate,

Microcrystalline cellulose,

Corn starch,

talc,

dye yellow (E104),

silica colloidal anhydrous dioxide,

magnesium stearate.

How to take, the dosage

In benign prostatic hyperplasia, the initial dose is 1 mg once daily before bedtime.

Gradually the dose is increased to 2-10 mg/day until optimal effect is achieved.

Therapeutic effect is usually observed within 2 weeks from the start of treatment.

The course of treatment should be 4-6 weeks to achieve a sustained effect.

In case of arterial hypertension, the drug is prescribed in an initial dose of 1 mg/day before bedtime.

Gradually the dose is increased until clinical effect is achieved.

The maintenance dose is 1-10 mg once daily.

The maximum daily dose is 20 mg. If the drug is temporarily discontinued, treatment is resumed according to the same regimen.

Interaction

In concomitant use of Kornam and beta-adrenoblockers, diuretics, calcium channel blockers, ACE inhibitors may increase the antihypertensive effect. Special caution is required when concomitant administration of terazosin and antihypertensive drugs of central action.

The absorption of terazosin is reduced with concomitant administration of adsorbents and antacids.

Adrenomimetics weaken the effect of terazosin.

Concomitant use of terazosin and NSAIDs may decrease antihypertensive effect due to inhibition of prostaglandin synthesis and retention of fluid and sodium ions.

Special Instructions

To prevent the development of orthostatic arterial hypotension, treatment should begin with administration of Kornam at a dose of 1 mg/day before bedtime, after which the patient should be in bed for 6-8 hours.

The risk of orthostatic arterial hypotension (“first-dose effect”) is highest within 30-90 minutes after drug administration and increased in patients receiving beta-adrenoblockers and diuretics simultaneously, with decreased RBC, hyposolic diet, and when resuming treatment with the drug after a break (several days).

In case of temporary discontinuation of treatment, therapy is resumed with the same dose. In the course of treatment the level of specific antigen of the prostate gland does not change. Before initiating therapy of benign prostatic hyperplasia, prostate cancer must be excluded.

The patient must be informed about the increased risk of orthostatic hypotension with alcohol consumption, prolonged standing or exercise, and hot weather.

Within 12 hours after the first dose, after increasing the dose, or after discontinuing therapy, it is not recommended to engage in potentially hazardous activities that require increased attention and quick psychomotor reactions.

Contraindications

With caution, prescribe the drug in angina, CHD, hepatic or renal failure, impaired cerebral circulation, type 1 diabetes.

Side effects

Cardiovascular system: rare – orthostatic hypotension.

CNS disorders: drowsiness, dizziness, asthenia.

Others: nasal congestion.

Cardiovascular system side: Orthostatic hypotension – “first-dose effect” (observed in 1% of patients, mostly receiving concomitant diuretics or beta-adrenoblockers), manifested by dizziness, tachycardia, fainting may occur; rarely, palpitations, peripheral edema, nasal congestion.

CNS disorders: rarely – dizziness, asthenia, somnolence, visual disturbances.

Hematopoietic system disorders: decrease (associated with hemodilution) of hematocrit, hemoglobin, leukopenia, hypoproteinemia, hypoalbuminemia.

Others: rarely – decreased potency, nausea.

Overdose

Symptoms: pronounced decrease in BP, impaired coordination of movements, fainting.

Treatment: it is necessary to lay the patient down with the head end of the bed.

If necessary, prescribe hypertensive agents, IV fluid administration.

Hemodialysis is not effective.

Pregnancy use

Cornam can be used in pregnancy and during breastfeeding if the potential benefit to the mother outweighs the possible risk to the fetus or infant.

Similarities